← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Auritec Pharmaceuticals, Inc.
Santa Monica, CA
$28,562,656
Total funding
31
Grants
Funding over time
peak $2.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,063,376 · 30
FDA$499,280 · 1
By mechanism
R44$21,762,726 · 12
R43$2,536,746 · 14
R33$1,384,184 · 1
U44$1,299,084 · 1
R61$868,774 · 1
U01$499,280 · 1
Investigators at Auritec Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes$1,025,000
R44 · FY2024 · AI
IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes$1,025,000
R44 · FY2023 · AI
Long-acting injectable tacrolimus for chronic immunosuppression$1,024,014
R44 · FY2022 · AI
Long-acting injectable tacrolimus for chronic immunosuppression$1,023,600
R44 · FY2023 · AI
IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes$1,000,000
R44 · FY2025 · AI
IND-enabling preclinical development of a sustained-release Pritelivir intravaginal ring for the treatment and prophylaxis of Genital Herpes in women$1,000,000
R44 · FY2020 · AI
Preclinical development of a tenofovir intravaginal ring for HIV prophylaxis$1,000,000
R44 · FY2011 · AI
IND-enabling preclinical development of a system for the multipurpose prevention of HIV and unintended pregnancy$999,998
R44 · FY2019 · AI
IND-enabling preclinical development of a system for the multipurpose prevention of HIV and unintended pregnancy$999,998
R44 · FY2020 · AI
Preclinical development of a tenofovir intravaginal ring for HIV prophylaxis$978,004
R44 · FY2012 · AI
Preclinical development of a tenofovir intravaginal ring for HIV prophylaxis$975,223
R44 · FY2013 · AI
IND-enabling preclinical development of a sustained-release Pritelivir intravaginal ring for the treatment and prophylaxis of Genital Herpes in women$860,561
R44 · FY2019 · AI
Longer-acting intravaginal formulation of buprenorphine$845,335
R44 · FY2021 · DA
Longer-acting intravaginal formulation of buprenorphine$845,335
R44 · FY2022 · DA
Depot calcineurin inhibitors to prevent graft rejection$839,479
R44 · FY2010 · AI
Clinical Safety and Pharmacokinetics of Sustained Release Depot Tacrolimus$766,264
U44 · FY2017 · AI
Automation of GMP manufacturing of HIV microbicide rings$698,040
R44 · FY2016 · MH
Clinical safety and pharmacokinetic studies of intravaginal rings releasing multiple antiretrovirals$664,015
R44 · FY2015 · HD
Clinical safety and pharmacokinetic studies of intravaginal rings releasing multiple antiretrovirals$637,265
R44 · FY2016 · HD
Depot intra-articular fluticasone for the treatment of arthritis$628,279
R44 · FY2014 · AR